Tripeptide–copper
complexCanine experimental model
Swaim et al. · 1996
Wound-healing signals in a specific local model.
A study in 12 mature English Pointers compared locally injected tripeptide–copper complex, an immunostimulant and saline in experimental pad wounds. The copper-complex group had higher type I collagen; the strongest early healing-rate findings were in the immunostimulant group.
Boundary of the evidenceA small experimental wound model does not establish general clinical benefit, a patch delivery system or a finished Repario product.
Read the primary study · PubMed ↗BPC-157Preclinical safety work
Xu et al. · 2020
Safety observations require formulation and context.
The published toxicology programme covered mice, rats, rabbits and dogs. Over 28 days of daily intramuscular dosing in beagles the authors set a no-observed-adverse-effect level of 0.5 mg/kg per day. Serum creatinine fell at the highest dose tested and returned to normal within two weeks of stopping. Histopathology of the liver, kidney and other organs was unremarkable in dogs.
Boundary of the evidenceTwenty-eight days in healthy young beagles does not establish safety for chronically ill patients, a different formulation or long-term use, and no carcinogenicity study has been published in any species. These are tolerability observations, not evidence of clinical benefit.
Read the primary study · Regulatory Toxicology and Pharmacology ↗BPC-157Rat & beagle pharmacokinetics
He et al. · 2022
Route and exposure are development questions.
Following the tested intravenous and intramuscular administration, the parent peptide’s reported half-life was under 30 minutes. Intramuscular bioavailability in beagles was approximately 45–51%.
Boundary of the evidencePharmacokinetic observations do not establish a therapeutic effect, a dosing protocol, oral availability or delivery through a patch or neck band.
Read the primary study · Frontiers in Pharmacology ↗ These research materials are not selected Repario ingredients. Exact molecular identity, formulation, route, population and endpoint must be matched before extrapolating from any paper. No patented protocol, marketing authorisation or finished-product clinical efficacy is claimed.
